WESTBOROUGH, Mass.--(BUSINESS WIRE)--
RXi Pharmaceuticals Corporation (RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company will be presenting an overview of the use of sd-rxRNAs® in the eye and highlighting specifically RXi’s work in the areas of retinoblastoma and proliferative vitreoretinopathy at the 2013 ARVO ( Association for Research in Vision and Ophthalmology) Annual Meeting.
On Monday, May 6, 2013 at 9:45 am PDT, Michael Byrne, Ph.D., of RXi Pharmaceuticals, will deliver a speaker presentation entitled “Development of sd-rxRNA for Retinoblastoma Therapy” during the Retinoblastoma: Pre-Clinical Models and Targeted Therapies session. Dr. Byrne’s presentation will be available on the Company's website.
On Thursday, May 9, 2013, 10:30-12:15 PDT, Dr. Byrne, along with collaborators Steven K. Fisher, Ph.D. and Geoffrey P. Lewis, Ph.D. from UCSB (University of California, Santa Barbara), will present a poster entitled “Novel Anti-CTGF RNAi Therapy for Treatment of Proliferative Vitreoretinopathy (PVR) and other Ocular Disorders” during the Proliferative Vitreoretinopathy session. The poster will be available on the Company’s website.
This conference is being held May 5-9, 2013 at the Washington State Convention Center, Seattle, WA. For more information visit: http://www.arvo.org
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi platform. Therapeutics that use RNA interference, or “RNAi,” have great promise because of their ability to down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi’s first RNAi product candidate, RXI-109, targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis), entered into human clinical trials in June 2012. For more information, please visit www.rxipharma.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, planned and future development of RXi Pharmaceuticals Corporation’s products and technologies. Forward-looking statements about expectations and development plans of RXi’s products involve significant risks, and uncertainties: risks that RXi may not be able to successfully develop its candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based product; risks that the development process for our product candidates may be delayed, risks related to development and commercialization of products by our competitors, risks related to our ability to control timing and terms of collaborations with third parties, and the possibility that other companies or organizations may assert patent rights preventing us from developing our products. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.
Tamara McGrillen, 508-929-3646